Merck logo

Merck

MRK | NYSE
Chart Builder DCF Calculator
$144.46
-$3.30 (-2.23%)
At close: Nov 16, 2026, 4:02 PM ET
$144.85
+$0.39 (+0.27%)
After-hours: Nov 16, 2026, 7:51 PM ET
-2.23%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
40.3
-0.5 pts
Fundamentals Average
Market Sentiment Neutral
Moat Wide
Sector Rank #521/1021 (Top 51%)

Why Price Moved

17 days ago
+2.18%

Shares are trading higher after the company report...

Key Statistics

Market Data

Market Cap $356.13B
1D Range
144.25 149.23
52W Range
92.86 156.45

Valuation (TTM)

PE 148.93
PB 8.49
EV/EBITDA 30.91

Valuation (NTM)

Forward PE 53.15
Forward PEG -2.17
Price Target $165.00
Loading financial charts...

Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broa...

Sector Healthcare
Employees 74,000
IPO Date Jan 13, 1978
Fiscal Year January - December

Latest News

Is Merck's Stock Still a Good Buy at $150?

11 hours ago · fool.com

Is Merck's Stock Still a Good Buy at $150?
He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

2 days ago · 247wallst.com

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

3 days ago · businesswire.com

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

3 days ago · businesswire.com

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
What Merck KGaA (MRK) Said on Its Q3 Earnings Call

4 days ago · marketbeat.com

What Merck KGaA (MRK) Said on Its Q3 Earnings Call
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

6 days ago · businesswire.com

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

8 days ago · businesswire.com

Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

8 days ago · zacks.com

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap

9 days ago · 247wallst.com

Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?

10 days ago · zacks.com

Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?

Earnings

Latest Earnings
Oct 29, 2026
EPS
$2.49
Beat +19.14%
REV
$18.09B
Beat +4.35%
Next Earnings
Feb 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
21
Consensus
Buy
Price Target
$165.00
Upside
+14.22%
Buy (15)
Hold (6)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.